2026 Q2 - tulosraportti
71 päivää sitten
‧1 t 0 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 8 000 | - | - | ||
| 7 000 | - | - | ||
| 5 000 | - | - | ||
| 15 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 12.8. | ||
2026 Q1 - tulosraportti 4.5. | ||
2025 Q4 - tulosraportti 11.3. | ||
2025 Q3 - tulosraportti 12.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
12.10.Well, PyCon Greece is moving. 500+ attendees; backend developers, DevOps engineers and tech leads, The type of crowd to market the new demo/platform to- and network with. Divio are a silver sponsor and are attending the event. Hopefully they are able to generate some leads and opportunities while there. https://2026.pycon.gr/en/12.10.The whole event is livestreamed for anyone curious and with time to kill. https://2026.pycon.gr/en/livestream/
·26.9. · MuokattuThe mispricing in this company and that investors are "dropping off" now, is almost incomprehensible? But a severe failing grade for the management and its historical inability to communicate with the market and primarily rely on dry regulatory press releases. Hope that there will be a change in that area soon. Assessed, an additional 25,000 - 50,000 usd more in MRR is needed for the company to get back on its feet. 25,000 usd in MRR would, assessed, provide operating cash flow neutrality, i.e., the company then stops burning cash in ongoing operations. An additional 25,000 USD in MRR would additionally, assessed, provide full self-funding, including development. Divio is understood to activate around 1.4 msek per quarter for its development work and would then cover this with it. Presumably, Divio receives these revenues through a renegotiated agreement with Fidelity as previous upfront discounts disappear and in combination with a potential expansion of that agreement (?) as well as perceived expansion of the Roche agreement. These two stable global companies and their revenues would thus provide total self-funding that also covers continuous development of Divio's offering/platform. If one adds to that improved gross margins which are already reasonably high today as well as growth via the agency strategy, the investment case is very positive. Divio's net debt is also zero after the latest share issue. P/S is now below 1 and the company is priced with an extreme risk discount as if Fidelity or Roche were to leave, which is completely unreasonable and illogical; especially given the new platform which is now understood to be under demonstration. Normally, this type of company is priced at least around P/S 3-5. If positive renegotiation with Fidelity and expansion with Roche with the mentioned MRR addition of 50,000 usd and thus full self-funding, the company reaches an annual turnover of around 39 msek in 2027. If we assume P/S to 3 for the valuation, which is reasonable and conservative given the company's position and prospects, this gives a valuation/share price of 3 x 39 msek / 600,174,745 shares = 0.195 sek (!). The share price today hovers around 0.05 sek, i.e., assessed a mispricing of 0.145 sek, which in that case with a changed valuation would give a rise of 390% (!). To this can then be added the customers who potentially join now via the agency strategy and those who potentially await onboarding waiting for Divio's new platform 2027. According to me and given the current position in the company, in the market, trends and also taking geopolitics into account, Divio is assessed as a fantastic turnaround case and extremely mispriced. Potentially there is a large upside ahead and it can become a rocket given the low liquidity in trading. Given self-funding, good growth and good margins, this type of company is normally valued around P/S 3-5 and EV/Sales around 3-6. The company is valued today at P/S around 0.90 and EV/Sales around 0.95. Given a positive outcome with only Fidelity and Roche and an annual turnover of around 39 msek according to the reasoning above and at current valuation, P/S drops to around 0.77 and EV/Sales to around 0.56. Then potentially additional revenues also come via the agency strategy. A completely absurd mispricing that the market is assessed will soon (?) close. Remains to be seen what is communicated now during autumn/winter. (! Reservation for "flawed thinking" - do your own due diligence.)In addition - on top of zero net debt - around 10 msek in cash and thus an assessed sufficiently long runway to achieve self-financing.
22.9.This is probably the bottom signal and true believers should rather buy more but Divio has been on the verge of a major breakthrough with great financial prospects and a cheap valuation for 7 years. In reality there has never been a dime of shareholder value created. Overpromise & underdeliver seems to be the theme. Most likely management is out to make money for themselves, are too incompetent to make it all work or the business idea just isn't viable. Look back on what they said over time and what actually happened a year or two later. It's always been worse or a lot worse than one would've thought. What's different now?23.9.Also, we should ask for clarification about what is going on with the Roche-collaboration. If the incentive to use Divio is to simplify and automate functions through the platform, why are there recurrent consultancies and fees? Are we getting ready to onboard a larger portion, or are the current loads not quite getting to an automated state?
·10.9.There isn't much time left of Q3 if they are to launch the demo platform. Are they again too optimistic or do we believe that they are on track? I must honestly say that I will be disappointed if they don't deliver on this as it was their very clear goal.They have already launched the demo, haven't they? They said so in the report, didn't they?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 56 521 | 56 521 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 56 521 | 56 521 | 0 | 0 |
2026 Q2 - tulosraportti
71 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 12.10.Well, PyCon Greece is moving. 500+ attendees; backend developers, DevOps engineers and tech leads, The type of crowd to market the new demo/platform to- and network with. Divio are a silver sponsor and are attending the event. Hopefully they are able to generate some leads and opportunities while there. https://2026.pycon.gr/en/12.10.The whole event is livestreamed for anyone curious and with time to kill. https://2026.pycon.gr/en/livestream/
- ·26.9. · MuokattuThe mispricing in this company and that investors are "dropping off" now, is almost incomprehensible? But a severe failing grade for the management and its historical inability to communicate with the market and primarily rely on dry regulatory press releases. Hope that there will be a change in that area soon. Assessed, an additional 25,000 - 50,000 usd more in MRR is needed for the company to get back on its feet. 25,000 usd in MRR would, assessed, provide operating cash flow neutrality, i.e., the company then stops burning cash in ongoing operations. An additional 25,000 USD in MRR would additionally, assessed, provide full self-funding, including development. Divio is understood to activate around 1.4 msek per quarter for its development work and would then cover this with it. Presumably, Divio receives these revenues through a renegotiated agreement with Fidelity as previous upfront discounts disappear and in combination with a potential expansion of that agreement (?) as well as perceived expansion of the Roche agreement. These two stable global companies and their revenues would thus provide total self-funding that also covers continuous development of Divio's offering/platform. If one adds to that improved gross margins which are already reasonably high today as well as growth via the agency strategy, the investment case is very positive. Divio's net debt is also zero after the latest share issue. P/S is now below 1 and the company is priced with an extreme risk discount as if Fidelity or Roche were to leave, which is completely unreasonable and illogical; especially given the new platform which is now understood to be under demonstration. Normally, this type of company is priced at least around P/S 3-5. If positive renegotiation with Fidelity and expansion with Roche with the mentioned MRR addition of 50,000 usd and thus full self-funding, the company reaches an annual turnover of around 39 msek in 2027. If we assume P/S to 3 for the valuation, which is reasonable and conservative given the company's position and prospects, this gives a valuation/share price of 3 x 39 msek / 600,174,745 shares = 0.195 sek (!). The share price today hovers around 0.05 sek, i.e., assessed a mispricing of 0.145 sek, which in that case with a changed valuation would give a rise of 390% (!). To this can then be added the customers who potentially join now via the agency strategy and those who potentially await onboarding waiting for Divio's new platform 2027. According to me and given the current position in the company, in the market, trends and also taking geopolitics into account, Divio is assessed as a fantastic turnaround case and extremely mispriced. Potentially there is a large upside ahead and it can become a rocket given the low liquidity in trading. Given self-funding, good growth and good margins, this type of company is normally valued around P/S 3-5 and EV/Sales around 3-6. The company is valued today at P/S around 0.90 and EV/Sales around 0.95. Given a positive outcome with only Fidelity and Roche and an annual turnover of around 39 msek according to the reasoning above and at current valuation, P/S drops to around 0.77 and EV/Sales to around 0.56. Then potentially additional revenues also come via the agency strategy. A completely absurd mispricing that the market is assessed will soon (?) close. Remains to be seen what is communicated now during autumn/winter. (! Reservation for "flawed thinking" - do your own due diligence.)In addition - on top of zero net debt - around 10 msek in cash and thus an assessed sufficiently long runway to achieve self-financing.
- 22.9.This is probably the bottom signal and true believers should rather buy more but Divio has been on the verge of a major breakthrough with great financial prospects and a cheap valuation for 7 years. In reality there has never been a dime of shareholder value created. Overpromise & underdeliver seems to be the theme. Most likely management is out to make money for themselves, are too incompetent to make it all work or the business idea just isn't viable. Look back on what they said over time and what actually happened a year or two later. It's always been worse or a lot worse than one would've thought. What's different now?23.9.Also, we should ask for clarification about what is going on with the Roche-collaboration. If the incentive to use Divio is to simplify and automate functions through the platform, why are there recurrent consultancies and fees? Are we getting ready to onboard a larger portion, or are the current loads not quite getting to an automated state?
- ·10.9.There isn't much time left of Q3 if they are to launch the demo platform. Are they again too optimistic or do we believe that they are on track? I must honestly say that I will be disappointed if they don't deliver on this as it was their very clear goal.They have already launched the demo, haven't they? They said so in the report, didn't they?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 8 000 | - | - | ||
| 7 000 | - | - | ||
| 5 000 | - | - | ||
| 15 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 12.8. | ||
2026 Q1 - tulosraportti 4.5. | ||
2025 Q4 - tulosraportti 11.3. | ||
2025 Q3 - tulosraportti 12.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 56 521 | 56 521 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 56 521 | 56 521 | 0 | 0 |
2026 Q2 - tulosraportti
71 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 12.8. | ||
2026 Q1 - tulosraportti 4.5. | ||
2025 Q4 - tulosraportti 11.3. | ||
2025 Q3 - tulosraportti 12.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- 12.10.Well, PyCon Greece is moving. 500+ attendees; backend developers, DevOps engineers and tech leads, The type of crowd to market the new demo/platform to- and network with. Divio are a silver sponsor and are attending the event. Hopefully they are able to generate some leads and opportunities while there. https://2026.pycon.gr/en/12.10.The whole event is livestreamed for anyone curious and with time to kill. https://2026.pycon.gr/en/livestream/
- ·26.9. · MuokattuThe mispricing in this company and that investors are "dropping off" now, is almost incomprehensible? But a severe failing grade for the management and its historical inability to communicate with the market and primarily rely on dry regulatory press releases. Hope that there will be a change in that area soon. Assessed, an additional 25,000 - 50,000 usd more in MRR is needed for the company to get back on its feet. 25,000 usd in MRR would, assessed, provide operating cash flow neutrality, i.e., the company then stops burning cash in ongoing operations. An additional 25,000 USD in MRR would additionally, assessed, provide full self-funding, including development. Divio is understood to activate around 1.4 msek per quarter for its development work and would then cover this with it. Presumably, Divio receives these revenues through a renegotiated agreement with Fidelity as previous upfront discounts disappear and in combination with a potential expansion of that agreement (?) as well as perceived expansion of the Roche agreement. These two stable global companies and their revenues would thus provide total self-funding that also covers continuous development of Divio's offering/platform. If one adds to that improved gross margins which are already reasonably high today as well as growth via the agency strategy, the investment case is very positive. Divio's net debt is also zero after the latest share issue. P/S is now below 1 and the company is priced with an extreme risk discount as if Fidelity or Roche were to leave, which is completely unreasonable and illogical; especially given the new platform which is now understood to be under demonstration. Normally, this type of company is priced at least around P/S 3-5. If positive renegotiation with Fidelity and expansion with Roche with the mentioned MRR addition of 50,000 usd and thus full self-funding, the company reaches an annual turnover of around 39 msek in 2027. If we assume P/S to 3 for the valuation, which is reasonable and conservative given the company's position and prospects, this gives a valuation/share price of 3 x 39 msek / 600,174,745 shares = 0.195 sek (!). The share price today hovers around 0.05 sek, i.e., assessed a mispricing of 0.145 sek, which in that case with a changed valuation would give a rise of 390% (!). To this can then be added the customers who potentially join now via the agency strategy and those who potentially await onboarding waiting for Divio's new platform 2027. According to me and given the current position in the company, in the market, trends and also taking geopolitics into account, Divio is assessed as a fantastic turnaround case and extremely mispriced. Potentially there is a large upside ahead and it can become a rocket given the low liquidity in trading. Given self-funding, good growth and good margins, this type of company is normally valued around P/S 3-5 and EV/Sales around 3-6. The company is valued today at P/S around 0.90 and EV/Sales around 0.95. Given a positive outcome with only Fidelity and Roche and an annual turnover of around 39 msek according to the reasoning above and at current valuation, P/S drops to around 0.77 and EV/Sales to around 0.56. Then potentially additional revenues also come via the agency strategy. A completely absurd mispricing that the market is assessed will soon (?) close. Remains to be seen what is communicated now during autumn/winter. (! Reservation for "flawed thinking" - do your own due diligence.)In addition - on top of zero net debt - around 10 msek in cash and thus an assessed sufficiently long runway to achieve self-financing.
- 22.9.This is probably the bottom signal and true believers should rather buy more but Divio has been on the verge of a major breakthrough with great financial prospects and a cheap valuation for 7 years. In reality there has never been a dime of shareholder value created. Overpromise & underdeliver seems to be the theme. Most likely management is out to make money for themselves, are too incompetent to make it all work or the business idea just isn't viable. Look back on what they said over time and what actually happened a year or two later. It's always been worse or a lot worse than one would've thought. What's different now?23.9.Also, we should ask for clarification about what is going on with the Roche-collaboration. If the incentive to use Divio is to simplify and automate functions through the platform, why are there recurrent consultancies and fees? Are we getting ready to onboard a larger portion, or are the current loads not quite getting to an automated state?
- ·10.9.There isn't much time left of Q3 if they are to launch the demo platform. Are they again too optimistic or do we believe that they are on track? I must honestly say that I will be disappointed if they don't deliver on this as it was their very clear goal.They have already launched the demo, haven't they? They said so in the report, didn't they?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 8 000 | - | - | ||
| 7 000 | - | - | ||
| 5 000 | - | - | ||
| 15 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 56 521 | 56 521 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 56 521 | 56 521 | 0 | 0 |